In this article, we will look at the 10 Cheap Robotics Stocks to Invest In Now.
Global Robotics Market Outlook
The robotics industry, which has grown modestly over the past few years, has suddenly picked up pace after the emergence of AI. According to Goldman Sachs’ Head of China Industrial Technology research, the total addressable market for humanoid robots is expected to reach $38 billion by 2035, an upgrade of sixfold from a previous projection of $6 billion in 2023.
We recently covered 8 Most Promising Robotics Stocks According to Hedge Funds.
According to the International Federation of Robotics (IFR), professional service robots experienced a 30% increase in sales in 2023. IFR’s statistics department noted that more than 205,000 robotics units were sold in 2023, with Asia-Pacific accounting for 80% of global robotics sales. Transportation and logistics service robots were in huge demand and accounted for 113,000 units built in 2023, up by 35% compared to 2022. Medical robots are also in high demand, and the number surged by 36% to almost 6,100 units in 2023. The demand for surgery and diagnostics robots was the highest as they registered growth of 14% and 25% year-over-year.
The US Robotics Market
The United States is home to 199 companies engaged in robotics, with 66% producing professional service robots, 27% consumer service robots, and 12% medical robots. China ranks second after the US with 107 service and medical robot manufacturers and Germany ranks third with 83 companies.
According to IFR, the US manufacturing companies have invested significantly in automation, and the industrial robot installations surged by 12% to 44,303 units in 2023. Whereas, robotics installations in the electrical and electronics industry increased to 5,120 units in 2023, up by 37% year-over-year.
Global X Robotics & Artificial Intelligence ETF (NASDAQ:BOTZ) and Robo Global Robotics and Automation Index ETF (NYSE:ROBO) have returned more than 11% over the last year, respectively. Given the rising demand for humanoids and automation systems, robotics stocks present a promising area for investors to explore.
With that, let’s take a look at the 10 cheap robotics stocks to invest in now.
Logistics robots filling packages in a warehouse, preparing for delivery.
Our Methodology
To determine the list of cheap robotics stocks to invest in, we shortlisted the companies mainly involved in robotics with an analyst upside of more than 25%. Cheap, in the context of this article, means stocks that Wall Street analysts believe are undervalued and will skyrocket to higher share prices. We have ranked the cheap robotics stocks to invest in based on their popularity among hedge funds, as of Q3 2024, in ascending order.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
10 Cheap Robotics Stocks to Invest in Now
10. Lifeward Ltd. (NASDAQ:LFWD)
Analyst Upside (as of January 11): 402.62%
No. of Hedge Fund Holders: 1
Lifeward Ltd. (NASDAQ:LFWD) is a medical device company. The company designs and develops wearable structures that assist individuals with disabilities to stand and walk again. In September 2024, the company changed its name from ReWalk Robotics Ltd. to Lifeward Ltd. The branding change occurred following the AlterG acquisition in August 2023. AlterG specializes in anti-gravity systems and makes athletic training devices such as treadmills. The company’s rebranding now depicts a broader image with the addition of a new rehabilitation and athletic training portfolio.
Lifeward Ltd. (NASDAQ:LFWD) continues to grow its business, and in Q3 FY24, the company posted a 39% year-over-year increase in revenue. The company expanded its Medicare coverage, reaching more than 17,000 people with potential access to another 25,000 individuals. Moreover, Lifeward’s ReWalk Exoskeleton technology is getting more attention.
With a new beginning, Lifeward Ltd. (NASDAQ:LFWD) has raised capital of almost $5 million from selling around 1.81 million ordinary shares at $2.75 apiece. The company will use the capital to boost its commercial efforts, working capital, and other corporate purposes. Wall Street analysts expect Lifeward Ltd. to increase its revenue by an average of almost 35% in the first two quarters of FY25, backed by a more diversified portfolio in medical wearables and athletic training equipment. The company ended Q3 with $10.7 million in cash and zero debt, setting the stage for future growth backed by a solid financial foundation.
9. Stereotaxis, Inc. (NYSE:STXS)
Analyst Upside (as of January 11): 111.27%
No. of Hedge Fund Holders: 10
Stereotaxis, Inc. (NYSE:STXS) is a medical robotics firm. The company specializes in producing robotic systems that assist doctors to perform complex heart procedures with greater precision. The company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices.
Stereotaxis, Inc. (NYSE:STXS) continues to impress, driven by rising demand for Genesis robotic systems and the thriving integration of Access Point Technologies (APT). In Q3 FY24, the company posted $9.2 million in revenue with an increase in both system and recurring revenues, up by a notable 18% year-over-year. By the end of October 2024, Stereotaxis had more than $13 million in cash and had zero debt.
Analysts and investors remain positive about STXS. The company has made major developments in its innovation strategy, including the most recent approval of its Magbot Magnetic Navigation ablation catheter in China for cardiac ablation procedures and GenesisX robotic system approval in November 2024. The GenesisX robotic system, useful in electrophysiology and across endovascular interventions, has already received CE approval in Europe and expects FDA approval in 2025, validating the improving robotics technology for heart-related procedures. The company is optimistic about continued revenue growth, driven by recent developments, and plans to enhance its product ecosystem and reach profitability without requiring additional financing.